Halozyme Therapeutics, Inc. (HALO) reported second-quarter 2024 adjusted earnings of 91 cents per share, which surpassed the Zacks Consensus Estimate of 78 cents. The company had recorded earnings of 74 cents per share in the year-ago period. Total revenues increased almost 5% year over year to $231.4 million in the second quarter. Revenues surpassed the Zacks Consensus Estimate of $211 million. The top line was driven by higher royalty payments from Roche (RHHBY) for Phesgo and higher sales of proprietary ...

| --- | --- | |---------------------------------------------------|-------| | | | | Halozyme Therapeutics, Inc. | | | Second Quarter 2024 Financial & Operating Results | | | NASDAQ: HALO | | | | | | August 6, 2024 | | | | | 1 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including the Company's 2 ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Tram Bui - Vice President of Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Jason Butler - Citizens JMP Cerena Chen - Wells Fargo Jessica Fye - JP Morgan Michael DiFiore - Evercore ISI Mitchell Kapoor - H.C. Wainwright Brendan Smith - TD Cowen Vikram Purohit - Morg ...

For the quarter ended June 2024, Halozyme Therapeutics (HALO) reported revenue of $231.35 million, up 4.7% over the same period last year. EPS came in at $0.91, compared to $0.74 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $210.92 million, representing a surprise of +9.69%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.78. While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.69 per share when it actually produced earnings of $0.79, delivering a surprise of 14.49%. Over the last f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ...

Exhibit 99.1 HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue of $231 million; Net Income of $93 million; Adjusted EBITDA of $137 million; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.91 1 Royalty Revenue Increased 12% YOY to $125 million ® ® Partner Approvals for Ocrevus SC in Europe and the UK and VYVGART Hytrulo for CIDP in the U.S. Maintain Recently Increased 2024 Financial Guidance: Total Revenue of $935 - $1,015 million, Representing YOY Growth of 13% - 22 ...

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the m ...

SAN DIEGO, July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating results on Tuesday, August 6, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, August 6, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I8719057. A live webcast and repla ...

But the risks certainly match the rewards. One of the main characteristics of biotech companies is that they depend heavily on drug approvals from the Food and Drug Administration (FDA) and patent protection upon treatment development, which makes it difficult to predict the future outlook of individual stocks. Biotech companies also need heavy investment into research and development (R&D) in order to remain competitive, which requires high cash reserves and aggressive borrowing. Moderna (MRNA) Using its M ...